IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+9.59%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$160M
AUM Growth
+$160M
(+23%)
Cap. Flow
+$25.8M
Cap. Flow
% of AUM
16.16%
Top 10 Holdings %
Top 10 Hldgs %
50.41%
Holding
94
New
20
Increased
20
Reduced
10
Closed
22
Top Buys
| 1 |
Medtronic
MDT
|
$6.77M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$4.84M |
| 3 |
Biogen
BIIB
|
$4.28M |
| 4 |
Cigna
CI
|
$3.98M |
| 5 |
Pfizer
PFE
|
$3.21M |
Top Sells
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
$3.41M |
| 2 |
ARTC
ARTHROCARE CORP
ARTC
|
$3.02M |
| 3 |
Gilead Sciences
GILD
|
$2.48M |
| 4 |
ITMN
INTERMUNE INC
ITMN
|
$2.21M |
| 5 |
DexCom
DXCM
|
$2.13M |
Sector Composition
| 1 | Healthcare | 88.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $13.5M | 6.22% |
44,000
+14,000
| +47% | +$4.28M |
|
2
Amgen
AMGN
$155B
| $12.8M | 5.93% |
104,000
+4,000
| +4% | +$493K |
|
3
Merck
MRK
$210B
| $11.6M | 5.38% |
205,000
+30,000
| +17% | +$1.7M |
|
|
4
Cigna
CI
$80.3B
| $8.16M | 3.77% |
97,500
+47,500
| +95% | +$3.98M |
|
5
Zimmer Biomet
ZBH
$21B
| $8.04M | 3.72% |
85,000
+5,000
| +6% | +$473K |
|
|
6
Medtronic
MDT
$119B
| $6.77M | 3.13% |
+110,000
| New | +$6.77M |
|
7
Viatris
VTRS
$12.3B
| $5.49M | 2.54% |
112,500
-2,500
| -2% | -$122K |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.84M | 2.24% |
+320,000
| New | +$4.84M |
|
|
TRNX
9
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $4.78M | 2.21% |
225,000
+25,000
| +13% | +$531K |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $4.45M | 2.06% |
210,000
+97,500
| +87% | +$2.07M |
|
11
Alkermes
ALKS
$4.78B
| $4.41M | 2.04% |
100,000
+25,000
| +33% | +$1.1M |
|
|
NVDQ
12
DELISTED
Novadaq Technologies Inc.
NVDQ
| $3.9M | 1.8% |
175,000
+90,000
| +106% | +$2.01M |
|
|
IPXL
13
DELISTED
Impax Laboratories, Inc.
IPXL
| $3.83M | 1.77% |
145,000
+95,000
| +190% | +$2.51M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $3.8M | 1.76% |
215,000
+15,000
| +8% | +$265K |
|
15
Puma Biotechnology
PBYI
$254M
| $3.65M | 1.69% |
35,000
+10,000
| +40% | +$1.04M |
|
|
16
Gilead Sciences
GILD
$140B
| $3.54M | 1.64% |
50,000
-35,000
| -41% | -$2.48M |
|
17
Ligand Pharmaceuticals
LGND
$3.15B
| $3.36M | 1.56% |
50,000
-25,000
| -33% | -$1.68M |
|
|
18
Pfizer
PFE
$141B
| $3.21M | 1.48% |
+100,000
| New | +$3.21M |
|
|
WMGI
19
DELISTED
Wright Medical Group Inc
WMGI
| $3.11M | 1.44% |
100,000
+30,000
| +43% | +$932K |
|
20
Incyte
INCY
$16.5B
| $3.08M | 1.42% |
57,500
-17,500
| -23% | -$937K |
|
|
ALXN
21
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.04M | 1.41% |
+20,000
| New | +$3.04M |
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $2.69M | 1.24% |
+55,000
| New | +$2.69M |
|
23
Cytokinetics
CYTK
$4.23B
| $2.66M | 1.23% |
280,000
+130,000
| +87% | +$1.24M |
|
24
Teva Pharmaceuticals
TEVA
$21.1B
| $2.64M | 1.22% |
+50,000
| New | +$2.64M |
|
|
ELGX
25
DELISTED
Endologix Inc
ELGX
| $2.48M | 1.15% |
192,500
+32,500
| +20% | +$418K |
|